Compared with lower-grade astrocytomas and normal brain tissue, TOP2A transcription levels in GBM patients increased significantly, which is a useful prognostic indicator and may guide temozolomide chemotherapy (Arivazhagan et al., 2012). The gene discussed is TOP2A; the disease is astrocytoma (excluding glioblastoma).